Quantitative immuno-positron emission tomography imaging of HER2-positlve tumor xenografts with an iodine-124 labeled anti-HER2 diabody

Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
Cancer Research (Impact Factor: 9.33). 03/2005; 65(4):1471-8. DOI: 10.1158/0008-5472.CAN-04-2008
Source: PubMed


Positron emission tomography (PET) provides an effective means of both diagnosing/staging several types of cancer and evaluating efficacy of treatment. To date, the only U.S. Food and Drug Administration-approved radiotracer for oncologic PET is (18)F-fluoro-deoxyglucose, which measures glucose accumulation as a surrogate for malignant activity. Engineered antibody fragments have been developed with the appropriate targeting specificity and systemic elimination properties predicted to allow for effective imaging of cancer based on expression of tumor associated antigens. We evaluated a small engineered antibody fragment specific for the HER2 receptor tyrosine kinase (C6.5 diabody) for its ability to function as a PET radiotracer when labeled with iodine-124. Our studies revealed HER2-dependent imaging of mouse tumor xenografts with a time-dependent increase in tumor-to-background signal over the course of the experiments. Radioiodination via an indirect method attenuated uptake of radioiodine in tissues that express the Na/I symporter without affecting the ability to image the tumor xenografts. In addition, we validated a method for using a clinical PET/computed tomography scanner to quantify tumor uptake in small-animal model systems; quantitation of the tumor targeting by PET correlated with traditional necropsy-based analysis at all time points analyzed. Thus, diabodies may represent an effective molecular structure for development of novel PET radiotracers.

Download full-text


Available from: Calvin Shaller, Jan 27, 2014
  • Source
    • "Genetic manipulation has led to the design of diabodies, triabodies and tetrabodies that have higher avidity and increased maintenance of circulation, thus promoting tumor uptake for a long time without compromising tissue penetration properties (Hudson 1998). It has been demonstrated that the optimal structure which has both high tissue penetration and enough retention with rapid clearance would be a diabody (55 kDa), which is constructed by noncovalently linking two scFv fragments (Robinson et al. 2005, Sundaresan et al. 2003). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer is one of the most important causes of death all over the world, which has not yet been treated efficiently. Although several therapeutic approaches have been used, some side effects such as toxicity and drug resistance have been observed in patients, particularly with chemotherapy. The nanoparticle-mediated drug delivery systems (DDS) have a great potential to improve cancer treatment by transferring therapeutic factors directly to the tumor site. Such a treatment significantly decreases the adverse effects associated with cancer therapy on healthy tissues. Two main strategies, including passive and active methods, have been considered to be effective techniques which can target the drugs to the tumor sites. The current review sheds some light on the place of nanotechnology in cancer drug delivery, and introduces nanomaterials and their specific characteristics that can be used in tumor therapy. Moreover, passive and active targeting approaches focus on antibodies, particularly single chain variable fragments (scFv), as a novel and important ligand in a drug delivery system.
    Artificial Cells 01/2015; DOI:10.3109/21691401.2014.998830 · 1.02 Impact Factor
  • Source
    • "This enhanced penetration could increase overall efficacy. The diabodies in particular have been shown to provide rapid tissue penetration, high target retention, and rapid blood clearance presumably as a result of their multi-valent nature and intermediate size (55 kDa) (161). The use of alternative antibody formats also opens up the possibility of delivering multiple therapies from one oncolytic virus. "
    [Show abstract] [Hide abstract]
    ABSTRACT: For the past 150 years cancer immunotherapy has been largely a theoretical hope that recently has begun to show potential as a highly impactful treatment for various cancers. In particular, the identification and targeting of immune checkpoints have given rise to exciting data suggesting that this strategy has the potential to activate sustained antitumor immunity. It is likely that this approach, like other anti-cancer strategies before it, will benefit from co-administration with an additional therapeutic and that it is this combination therapy that may generate the greatest clinical outcome for the patient. In this regard, oncolytic viruses are a therapeutic moiety that is well suited to deliver and augment these immune-modulating therapies in a highly targeted and economically advantageous way over current treatment. In this review, we discuss the blockade of immune checkpoints, how oncolytic viruses complement and extend these therapies, and speculate on how this combination will uniquely impact the future of cancer immunotherapy.
    Frontiers in Immunology 02/2014; 5:74. DOI:10.3389/fimmu.2014.00074
  • Source
    • "However, decreased immunogenicity and univalent antigen binding of scFvs have limited its application [17] [18] [19]. To overcome these limitations, both covalent dimeric scFv (di-scFv) and noncovalent diabody constructs have been studied; as bivalent molecules, they exhibit greater avidity than the smaller univalent scFv fragments [20] [21] [22] [23]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Our goal is to compare the immunogenicity and the extent of immunologic reactivity between bispecific and mono anti-idiotype vaccines. We previously obtained two human anti-Id antibody fragments fuse5-G22, fuse5-I50 by phage display technology which were mimics of the antigens from nasopharyngeal carcinoma cell line (HNE2). In this study, we developed and characterized a bispecific anti-Id antibody vaccine G22-I50 and its parent monovalent antibody vaccines G22 and I50. The efficacy of G22-I50, G22, and I50 as tumor vaccines was evaluated in Balb/c mice with three injections of these vaccines adjuvanted with Freund's adjuvant. Mice immunized with G22-I50 exhibited comparable levels of antibody titers and stronger binding inhibition capabilities. Spleen cells from G22-I50-immunized mice gave a significant proliferative response and higher expression level of IFN-gamma and IL-2.These results suggested that bispecific anti-Id antibody vaccine was able to induce more powerful humoral and cell-mediated immune responses, which might make it to be a potential vaccine candidate for the therapy of nasopharyngeal carcinoma.
    International immunopharmacology 04/2010; 10(6):707-12. DOI:10.1016/j.intimp.2010.04.001 · 2.47 Impact Factor
Show more